Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Orbit International Power Group Reports October Bookings of About $1.7 Million

Orbit International Power Group Reports October Bookings of About $1.7 Million

BitgetBitget2026/11/06 13:45
  • Orbit International's power group booked approximately $1.7 million in October 2026, its fourth straight month above $1 million.
  • Bookings through October 31 rose 42.9% from the comparable prior-year period, exceeding the full-year 2025 total.
  • Year-to-date VPX power supply bookings exceeded $5 million for the first time, up 94.6% from the prior-year period.
  • October orders included approximately $775,000 in VPX power supplies from a large defense customer.
  • Deliveries under the October contracts have begun, with completion expected in the first quarter of 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orbit International Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611060845PRIMZONEFULLFEED9871925) on November 06, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12